Alamar Biosciences

08/27/2026

We’re excited to welcome Panomics Biosciences to the Alamar Certified Service Provider (CSP) network!

With expertise in bioanalytical testing, assay development, contract manufacturing, and diagnostic services, Panomics Biosciences helps organizations advance research and bring innovative technologies to market.

Researchers can now access NULISA™ precision proteomics services through Panomics Biosciences, expanding access to ultra-sensitive protein biomarker analysis in Australia.

Learn more about Panomics Biosciences: https://na2.hubs.ly/H07sTdL0
Explore our Certified Service Provider network: https://na2.hubs.ly/H07sSJP0

08/24/2026

We’re excited to welcome Infinity Scope Multi-Omics to the Alamar Certified Service Provider (CSP) network!

Infinity Scope specializes in spatial multi-omics testing services, covering sample processing, sequencing, R-based bioinformatics analysis, and full-report delivery to help researchers investigate complex biological systems with greater depth and spatial context.

Through the Alamar CSP network, researchers can now access NULISA™ precision proteomics alongside Infinity Scope’s broader multi-omics capabilities.

Learn more about Infinity Scope Multi-Omics: https://na2.hubs.ly/H07nj3x0
Explore our Certified Service Provider network: https://na2.hubs.ly/H07nj2F0

08/18/2026

🚀 Applications are now open for the NULISA Immunology Grant Program.

Four research projects will be selected to receive access to the NULISAseq™ Immune 340 Panel through our Technology Access Program (TAP).

The Immune 340 Panel enables comprehensive profiling of ~340 proteins spanning innate and adaptive immunity, including cytokines, chemokines, immune checkpoints, and cell-death pathways—all from a single 25 µL plasma or serum sample.

With attomolar sensitivity and broad dynamic range, the panel is designed to detect low-abundance immune mediators alongside more abundant proteins, supporting research into disease biology, biomarker discovery, therapeutic response, and other translational applications.

What could a more complete view of the immune landscape uncover in your research?

Apply by October 15, 2026.

Learn more and apply through the link below or scan the QR code: https://alamarbio.com/nulisa-immunology-grant-immune-340-panel/

08/12/2026

We're pleased to welcome PBL Assay Science to the Alamar Certified Service Provider (CSP) network.

For more than 30 years, PBL Assay Science has brought deep expertise in immunoassays and biomarker testing, specializing in singleplex and multiplex assays for some of the toughest-to-measure proteins in their biological context. With a strong foundation in interferon and cytokine biology, PBL supports drug development, translational, and clinical research through assay development, validation, and testing services.

As an Alamar CSP, PBL Assay Science will expand access to NULISA™ precision proteomics, combining their biomarker and assay expertise with NULISA's high-plex, ultra-sensitive capabilities to support comprehensive protein profiling across a broad range of research applications.

Learn more about PBL Assay Science: https://na2.hubs.ly/H078cGd0
Explore our Certified Service Provider network: https://na2.hubs.ly/H078h_Y0

08/10/2026

🚀 A significant step forward for neurodegenerative disease research.

We're proud to expand our collaboration with the Alzheimer's Disease Data Initiative (ADDI) and Gates Ventures, adding 86,000 samples to a growing global effort to advance neurodegenerative disease research. Using the NULISAseq™ Neuro 220 Panel, this initiative will help researchers move beyond single biomarkers toward a deeper understanding of disease heterogeneity, subtypes, and progression. By 2027, the combined dataset is expected to exceed 140,000 samples across diverse cohorts and geographies, creating a powerful resource for the global research community and helping accelerate precision medicine approaches to neurodegenerative disease.

This expansion marks an important step toward generating one of the largest proteomics datasets ever assembled for neurodegenerative disease, helping enable new insights into the biology that drives these complex conditions.

Read the full release: https://na2.hubs.ly/H075c_g0

07/29/2026

Broad enough to discover. Sensitive enough to trust.

The NULISAseq™ Immune 340 Panel combines ~340 immune-related proteins with attomolar sensitivity to provide a more complete view of immune biology. Designed to capture a broader view of the immune proteome in one assay, it enables researchers to detect low-abundance biomarkers across key immune pathways from a single plasma or serum sample with a fully automated workflow.

Download the data sheet to explore the panel content, assay performance, and technical specifications that power deeper immune profiling.

📄 Download the data sheet: https://na2.hubs.ly/H06Y1520

07/28/2026

🚀 Introducing the NULISAseq™ Immune 340 Panel

Advance immune biomarker discovery with our most comprehensive immune profiling solution to date. Combining ~340 immune proteins with attomolar sensitivity, the Immune 340 Panel delivers a broad view of the immune proteome from a single plasma or serum sample.

Designed to support translational and clinical research, the panel enables simultaneous measurement of immune checkpoints, cytokines, chemokine networks, complement biology, cytotoxic effectors, and cell-death pathways, providing a more complete picture of immune biology without the need to run multiple targeted panels.

Why it matters:
✅ Comprehensive immune profiling across key immune pathways
✅ Attomolar sensitivity for low-abundance biomarker detection
✅ Broad dynamic range to quantify both high- and low-abundance proteins in a single assay
✅ Fully automated workflow on the ARGO™ HT platform for reproducible, scalable analysis
✅ Robust detectability and compatibility for at-home sampling and longitudinal studies

As researchers seek more complete insights from every sample, the Immune 340 Panel provides the depth and performance needed to uncover meaningful immune biology with greater confidence.

Learn more about the NULISAseq™ Immune 340 Panel: https://na2.hubs.ly/H06W_sJ0

07/24/2026

"The old idea that we could measure one "magic marker" and have it tell us everything has already become impractical. Even measuring one or two markers isn't going to be enough for every clinical question."— Steve Williams, PhD

At , NeurologyLive spoke with our Chief Scientific Officer, Stephen Williams, PhD, about the evolving role of blood-based biomarkers in Alzheimer's disease. From the promise of eMTBR-tau and multiplex biomarker testing to the potential for AI-driven models to simplify complex biological data, the interview explores what's driving the next wave of innovation in Alzheimer's biomarker research.

Read the full interview:

As blood-based biomarkers continue to reshape the landscape of Alzheimer disease (AD) diagnosis and research, advances in highly sensitive detection technologies are enabling researchers to investigate a broader range of disease-related pathologies. Among these emerging markers is extracellular mid-...

07/23/2026

Another trusted partner has joined the Alamar Biosciences Certified Service Provider (CSP) Program.

We're pleased to welcome Sequanta Technologies, a leading multi-omics CRO providing integrated genomics, transcriptomics, proteomics, microbiomics, and multi-omics solutions for pharmaceutical, biotechnology, and academic research. With NULISA™ technology in their portfolio, they're expanding access to ultra-sensitive, high-plex proteomics for biomarker discovery and translational research.

As we continue to grow our global CSP network, we're making advanced proteomic solutions more accessible through trusted partners around the world.

Learn more about the CSP Program: https://na2.hubs.ly/H06R57p0
Learn more about Sequanta Technologies: https://na2.hubs.ly/H06R21Y0

07/22/2026

This , we're inspired by the progress being made in neurological research. From blood-based biomarkers to deeper insights into disease biology, new technologies are helping researchers expand what's possible in the study of brain health and neurodegenerative disease.

As collaboration, innovation, and scientific discovery continue to accelerate, we're excited to see how the next generation of research will deepen our understanding of neurological disease and help shape the future of neuroscience.